RxDoctor Payments Data

Kenneth Weinberg, MD

Clinical Cardiac Electrophysiology · Winfield, ILNPI 1922069574

Payments from drug & device makers

$2,679in general payments, 2019–2025

Across 174 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$463
  • Pfizer$450
  • Boston Scientific$282
  • Medtronic$281
  • E.r. Squibb & Sons, L.L.C.$273
  • Sanofi-aventis U.S. LLC$175
  • plus $756 from 11 others

What the payments were for

  • Food & beverage$2,679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,679 in reported general payments places this provider in the 10th percentile of 158 clinical cardiac electrophysiology providers in Illinois.

See all clinical cardiac electrophysiology providers in Illinois

Medicare billing

Part B allowed, 2024
$401,230
Medicare patients
1,528
Services billed
5,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban589$829,683
XareltoRivaroxaban349$433,171
MultaqDronedarone Hcl38$81,541
Propafenone Hcl ErPropafenone Hcl71$16,121
Metoprolol Succinate752$13,078
Flecainide Acetate236$11,325
Amiodarone Hcl286$5,282
Dabigatran EtexilateDabigatran Etexilate Mesylate13$4,381
Propafenone Hcl59$2,544
SotalolSotalol Hcl65$1,983
Mexiletine Hcl13$1,744
Digoxin79$1,672
Diltiazem 24hr Er (Cd)Diltiazem Hcl97$1,428
Diltiazem 24hr ErDiltiazem Hcl30$1,382
Dilt-XrDiltiazem Hcl46$1,306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$450$829,683589 claims
Johnson & JohnsonXarelto$17$433,171349 claims
Sanofi-aventis U.S. LLCMultaq$175$81,54138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 158 clinical cardiac electrophysiology providers in Illinois.

Other clinical cardiac electrophysiology in Winfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →